People with knee arthritis and diabetes who take GLP-1 drugs like Ozempic seem to need knee surgery less often — 1.7% of them did over 6 years, compared to 5.9% who didn’t take the drugs — and some of this benefit comes from losing weight.
See the scientific wording
In adults with knee osteoarthritis and type 2 diabetes, the use of GLP-1 receptor agonists is associated with a lower incidence of knee surgery, including total knee arthroplasty and arthroscopic procedures, with a 1.7% incidence among users compared to 5.9% among non-users over a 6-year period, and approximately one-third of this protective association is mediated by weight loss.
Unverified — no studies directly back this
We haven't found enough studies to verify this claim yet.
Score breakdown, mechanism chain, raw evidence, ideal studies needed
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
People with knee arthritis and diabetes who take GLP-1 drugs like Ozempic seem to need knee surgery less often — 1.7% of them did over 6 years, compared to 5.9% who didn’t take the drugs — and some of this benefit comes from losing weight.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of GLP-1 Receptor Agonists and Risk of Knee Surgery in Adults with Osteoarthritis and Type 2 Diabetes
Systematic review of longitudinal studies and RCTs in adults with knee osteoarthritis and type 2 diabetes comparing GLP-1 agonist users to non-users, with knee surgery as primary outcome and weight loss as a mediator variable, using standardized surgical outcome definitions and mediation analysis.
Randomized Controlled Trial of Semaglutide vs Placebo on Knee Surgery Incidence in Adults with Knee Osteoarthritis and Type 2 Diabetes
Double-blind, placebo-controlled RCT in adults with knee osteoarthritis and type 2 diabetes, randomizing participants to GLP-1 agonist (e.g., semaglutide) or placebo for 6 years, with knee surgery (TKA or arthroscopy) as primary endpoint and serial weight measurements for mediation analysis.
Prospective Cohort Study of GLP-1 Agonist Use and Knee Surgery Risk in Diabetic Patients with Osteoarthritis
Multicenter prospective cohort of adults with knee osteoarthritis and type 2 diabetes, comparing incidence of knee surgery over 6 years between GLP-1 agonist users and matched non-users, with detailed covariate adjustment and formal mediation analysis for BMI change.
Case-Control Study of GLP-1 Agonist Use in Patients with Knee Osteoarthritis and Diabetes Who Underwent Knee Surgery vs Those Who Did Not
Nested case-control study within a large diabetes-osteoarthritis cohort, matching cases (knee surgery) to controls (no surgery) on age, sex, BMI, and diabetes duration, then comparing prior GLP-1 agonist exposure and weight trajectories.
Cross-Sectional Analysis of GLP-1 Agonist Use and History of Knee Surgery in Adults with Knee Osteoarthritis and Diabetes
Cross-sectional survey or database analysis of adults with knee osteoarthritis and type 2 diabetes, assessing current or past GLP-1 agonist use and history of knee surgery, with adjustment for BMI and other confounders.